Suppressive effects of the new antirheumatic drug KE-298 on TNF-α-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid synoviocytes

Drugs under Experimental and Clinical Research

Volumn 24, Issue 2, 1998, Pages 67-71

  Takahashi, S ^a,b   Inoue, T ^a   Higaki, M ^a   Mizushima, Y ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ESONARIMOD; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PROSTAGLANDIN E2; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DINOPROSTONE; HUMANS; INTERLEUKIN-6; METALLOENDOPEPTIDASES; PHENYLPROPIONATES; PROTEASE INHIBITORS; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031786051     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Brennan F.M., Maini R.N., Feldmann M. Scientific reviews in rheumatology. Br. J. Rheum., 31, 293, 1992.
2. Krane S.M., Conca W., Stephenson M.L., Amento A.P., Goldring M.B. Mechanisms of matrix degradation in rheumatoid arthritis. Ann. N. Y. Acad. Sci., 580, 340, 1990.
3. Docherty A.J., Lyons A., Smith B.J., Wright A.M., Stephens P.A., Harris T.J., Murphy G., Reynolds J.J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroidpotentiating activity. Nature, 318, 66, 1985.
4. Boone T.C., Johnson M.J., De Clerck Y.A., Langley K.A. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc. Natl. Acad. Sci. USA., 87, 2800, 1990.
5. Pavloff N:, Staskus P.W., Kishnani N.S., Hawkes S.P. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem., 267, 17321, 1992.
6. Welgus H.G., Jeffrey J.J., Eisen A.Z., Roswit W.T., Stricklin G.P. Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll. Relat. Res., 5, 167, 1985.
7. Herron G.S., Banda M.J., Clark A.J., Gavrilovic J., Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and strometysin activities is regulated by endogenous inhibitors. J. Biol. Chem., 261, 2814, 1986.
8. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., Woessner J.F. Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest., 84, 678, 1989.
9. Yasuda Y., Inoue T., Takeshita K. Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298. Drugs Exptl. Clin. Res., 22, 1, 1996.
10. Takeshita K., Fukazawa A., Futaki N., et al. Immunopharmacological studies of new 3-benzoil-4-mercaptobutyric acid. Immunomodulating effects. Arzneim. Forsch. Drug Res., 38, 537, 1988.
11. Hamamoto M., Kobayashi K., Yamagata N., et al. Suppression of pulmonary granulomatous inflammation by immunomodulating agents. Agents Actions, 37, 99, 1992.
12. Kotake S., Sato K., Kim K.J., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res., 11, 88, 1996.
13. Kaji H., Sugimoto T., Kanatani M., Fukase M., Kumegawa M., Chihara K. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res., 11, 62, 1996.
14. Hsu J.C. The factor analytic approach to simultaneous confidence interval for multiple comparisons with the best. J. Comput. Statis. Graph., 1, 151, 1992.
15. Ito A., Nose T., Takahashi S., Mori Y. Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Lett., 360, 75, 1995.
16. Takahashi S., Inoue T., Higaki M., Mizushima Y. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflamm. Res., 46, 320, 1997.